Drug Pipeline Database & Screener

Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Volume
Avg Daily Volume
Relative Volume
Price to Book
Open
Prev Close
EST EPCD
Updated
$22.50
-0.41  -1.79%
20.9 million
$470.1 million
105.2 thousand
130.7 thousand
0.8
$30.41
$22.46
$22.91
11/26/2021
Tap to view 3 drugs
Drug Indication Stage News
AKB-4924 (GB004) - SHIFT-UC Ulcerative Colitis Phase 2 Phase 2 top-line data due 2Q 2022.
Razuprotafib (AKB-9778) Open-angle glaucoma (OAG) Phase 2 Phase 2 data met primary endpoint with twice-daily dose group but not with once-daily group.
FYARRO PEComa​ Approved Approved November 23, 2021.
$116.51
-2.15  -1.81%
1.8 billion
$206 billion
5 million
6.1 million
0.82
$15.21
$117.61
$118.66
11/26/2021
Tap to view 57 drugs
Drug Indication Stage News
BOTOX Forehead lines Approved Approval (third indication) announced October 3, 2017.
Depatuxizumab mafodotin (ABT-414) Glioblastoma (rGBM) Phase 3 Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
IMBRUVICA (Ibrutinib) Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
IMBRUVICA (Ibrutinib) Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA (Ibrutinib) Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
VRAYLAR (cariprazine) Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
QULIPTA (Atogepant) Chronic migraine Approved Approved September 28, 2021.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 data due 2021.
ABICIPAR Age-related macular degeneration (AMD) CRL CRL issued June 26, 2020.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
VENCLEXTA (venetoclax) (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
VENCLEXTA (venetoclax) - CANOVA Relapsed or refractory multiple myeloma Phase 3 Phase 3 data due in 2021.
SKYRIZI (risankizumab) Psoriasis Approved FDA approval announced April 23, 2019.
IMBRUVICA (Ibrutinib) Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
RINVOQ (Upadacitinib) Atopic Dermatitis PDUFA PDUFA date early 3Q 2021 not met. The FDA cited its ongoing review of Pfizer's post-marketing study, ORAL Surveillance, evaluating tofacitinib in patients with rheumatoid arthritis for the delay.
IMBRUVICA (Ibrutinib) Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
GLECAPREVIR / PIBRENTASVIR (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
ORILISSA (Elagolix) Uterine Fibroids Approved FDA approval announced May 29, 2020.
ORILISSA (Elagolix) Endometriosis Approved FDA approval announced July 24, 2018.
UBRELVY (Ubrogepant) Migraine Approved FDA Approval announced December 23, 2019. Oral presentation of additional data September 11, 2021.
RINVOQ (Upadacitinib) Rheumatoid arthritis Approved FDA Approval announced August 16, 2019.
IMBRUVICA (Ibrutinib) and GAZYVA (Obinutuzumab) Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Approved FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
VENCLEXTA (venetoclax) First line unfit AML Approved FDA approval announced November 21, 2018.
RINVOQ (Upadacitinib) - U-ACHIEVE Ulcerative colitis NDA Filing NDA filed September 16, 2021.
VENCLEXTA (venetoclax) and GAZYVA (obinutuzumab) Chronic Lymphocytic Leukemia Approved FDA approval announced May 15, 2019.
IMBRUVICA (Ibrutinib) Pancreatic cancer Phase 3 Phase 3 primary endpoint not met (PFS/OS).
BOTOX Lower limb spasticity Approved FDA Approval announced October 24, 2019.
BOTOX Upper limb spasticity Approved FDA Approval announced June 21, 2019.
JUVÉDERM VOLUMA Mid-Face Injection Via Cannula Approved FDA Approval announced September 3, 2019.
IMBRUVICA (ibrutinib) and RITUXAN (rituximab) Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approved FDA Approval announced April 21, 2020.
SKYRIZI (risankizumab) vs COSENTYX (secukinumab) Plaque psoriasis Phase 3 Phase 3 trial met primary endpoint - January 14, 2020.
RINVOQ (Upadacitinib) Psoriatic arthritis PDUFA PDUFA estimate June 25, 2021 will not be met - noted June 25, 2021.
SKYRIZI (risankizumab) - MOTIVATE Crohn’s Disease NDA Filing NDA submission to FDA for the treatment of patients 16 years and older with moderate to severe Crohn's disease, September 20, 2021.
SKYRIZI (risankizumab) - (KEEPSAKE2) Psoriatic Arthritis Phase 3 Phase 3 trial met primary endpoint - January 5, 2021. Phase 3 52-week data from open-label extension showed that 58% of patients achieved American College of Rheumatology 20 (ACR20) response. Among patients initially treated with risankizumab, 32% achieved ACR50 response, and 17% achieved ACR70 response at one year. Three major adverse cardiac events (MACE) were reported, noted September 30, 2021.
RINVOQ (Upadacitinib) Atopic dermatitis Phase 3 Phase 3 data met co-primary endpoints - June 18, 2020. Second Phase 3 trial also met primary endpoint - July 21, 2020. Phase 3b data displayed among the 32 patients who did not achieve EASI 75 on dupilumab, 88 percent, 69 percent and 22 percent of those patients achieved EASI 75, EASI 90 and EASI 100, respectively, after 16 weeks on upadacitinib, noted September 30, 2021.
VENCLEXTA (venetoclax) - (VIALE-A) Acute Myeloid Leukemia (AML) Approved FDA approval announced October 16, 2020.
IMBRUVICA (Ibrutinib) and prednisone Chronic Graft Versus Host Disease Phase 3 Phase 3 trial ongoing.
ABBV-951 (foslevodopa/foscarbidopa) Parkinson's disease Phase 3 Phase 3 data reported that trial met primary endpoint, and was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations, noted October 28, 2021.
JUVÉDERM VOLUMA Augmentation of the chin region Approved FDA Approval announced June 15, 2020.
BOTOX Neurogenic Detrusor Overactivity Approved FDA approval announced February 10, 2021.
RINVOQ (upadacitinib) Active Ankylosing Spondylitis PDUFA PDUFA estimate June 25, 2021 will not be met - noted June 25, 2021. Phase 3 data noted that trial met primary endpoint, and all secondary endpoints, noted October 7, 2021.
VUITY Presbyopia Approved Approved October 29, 2021.
VRAYLAR (cariprazine) Major depressive disorder Phase 3 Phase 3 study 3111-301-001 met primary endpoint and demonstrated statistically significant change from baseline to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo. However, study 3111-302-001 did not meet its primary endpoint, noted October 29, 2021.
RINVOQ (Upadacitinib) Ulcerative Colitis (maintenance) Phase 3 Phase 3 trial met primary and all secondary endpoints - June 29, 2021.
RINVOQ (upadacitinib) Crohn's disease (induction/maintenance) Phase 3 Phase 3 data due 2021.
IMBRUVICA (Ibrutinib) - (SHINE) Mantle Cell Lymphoma Phase 3 Phase 3 data due 2021.
IMBRUVICA (Ibrutinib) + VENCLEXTA - Venetoclax (GLOW) Chronic Lymphocytic Leukemia Phase 3 Phase 3 data to be presented at ASH December 11, 2021.
DALVANCE (dalbavancin) Acute bacterial skin and skin structure infections (ABSSSI) - pediatric Approved FDA approval announced July 23, 2021.
BOTOX Upper Limb Spasticity Approved FDA approval announced July 29, 2021.
SKYRIZI (risankizumab) - (KEEPSAKE 1) Psoriatic Arthritis Phase 3 Phase 3 52-week data from open-label extension showed that 70% of patients achieved American College of Rheumatology 20 (ACR20) response. Among patients initially treated with risankizumab, 43% achieved ACR50 response, and 26% achieved ACR70 response at one year. Two deaths not related to the study drug per investigator were noted September 30, 2021. Phase 3 data noted 24-weeks of treatment with risankizumab resulted in greater improvements in PsA signs and symptoms compared with placebo with no new safety signals, reported November 5, 2021.
RINVOQ (upadacitinib) - SELECT-AXIS 2 Non-radiographic axial spondyloarthritis Phase 3 Phase 3 study met primary endpoint, and 12 of 14 secondary endpoints. The proportion of patients with adverse events leading to discontinuation, serious adverse events and serious infections were 2.6 percent/2.6 percent/1.3 percent for upadacitinib, respectively, noted October 7, 2021.
Venetoclax Multiple myeloma Phase 3 Phase 3 overall survival results to be presented at ASH December 11, 2021.
Venetoclax Plus Daratumumab and Dexamethasone Multiple Myeloma Phase 1/2 Phase 1/2 safety and preliminary efficacy data from expansion cohort to be presented as ASH December 13, 2021.
$13.99
-0.45  -3.12%
281.6 million
$3.9 billion
1.1 million
2.4 million
0.46
$4.13
$14.45
$14.44
11/26/2021
Tap to view 2 drugs
Drug Indication Stage News
BamlanivimabLY-CoV555 COVID-19 Antibody Approved Emergency Use Authorization (EUA) announced November 9, 2020.
Bamlanivimab and Etesevimab COVID-19 Anti-body Approved Emergency Use Authorization (EUA) expanded, announced September 16, 2021.
$0.73
-0.03  -3.57%
101.9 million
$74.4 million
723.6 thousand
771.2 thousand
0.94
$0.94
$0.75
$0.76
11/26/2021
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 (Transpher B) Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 two-year neurocognitive data due 2H 2022.
EB-101 - VITAL Recessive dystrophic epidermolysis bullosa (RDEB) Phase 3 Phase 3 enrollment completion expected Q1 2022, with top-line data due 3Q 2022.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 updated safety data released February 12, 2021. Phase 1/2 pivotal data due in 2022.
ABO-202 CLN1 disease (Infantile Batten disease) Phase 1/2 Phase 1/2 trial planned.
$8.27
-0.73  -8.11%
40.5 million
$334.7 million
49.1 thousand
122.5 thousand
0.4
$1.43
$8.74
$9.00
11/26/2021
Tap to view 1 drug
Drug Indication Stage News
ACU193 Alzheimer’s disease Phase 1 Phase 1 first patient dosed October 2021. Data due by the end of 2022.
$18.79
-0.99  -5.01%
160.8 million
$3 billion
890.8 thousand
1.3 million
0.71
$5.32
$19.45
$19.78
11/26/2021
Tap to view 8 drugs
Drug Indication Stage News
NUPLAZID (pimavanserin) CLARITY-2 and CLARITY-3 Adjunctive Treatment in Patients With Major Depressive Disorder Phase 3 Phase 3 trial did not meet primary endpoint - July 20, 2020.
NUPLAZID (pimavanserin) Advance-2 Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 3 Phase 3 trial initiated 3Q 2020.
NUPLAZID (pimavanserin) Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 data did not meet primary endpoint - July 22, 2019.
NUPLAZID (pimavanserin) Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
NUPLAZID (pimavanserin) Alzheimer’s disease psychosis CRL CRL announced April 5, 2021.
Trofinetide (LAVENDER) Rett Syndrome Phase 3 Phase 3 data due 4Q 2021.
ACP-044 Postoperative pain following bunionectomy surgery Phase 2 Phase 2 top-line data due 1Q 2022.
ACP-044 Pain associated with osteoarthritis Phase 2 Phase 2 trial initiated 2Q 2021.
$2.20
-0.06  -2.65%
14.3 million
$31.5 million
28.5 thousand
361.8 thousand
0.08
$14.67
$2.20
$2.26
11/26/2021
Tap to view 4 drugs
Drug Indication Stage News
EDSIVO (celiprolol) Vascular Ehlers-Danlos Syndrome Phase 3 CRL issued June 25, 2019. Phase 3 IND submission planned for 4Q 2021, with trial initiation due in 1Q 2022.
ACER-001 Urea cycle disorder (UCD) PDUFA PDUFA date June 5, 2022.
Osanetant (ACER-801) induced Vasomotor Symptoms (iVMS) Phase 1/2 Phase 1/2 trial to be initiated 1Q 2022.
ACER-2820 (emetine) COVID-19 Phase 2/3 Phase 2/3 trial initiation is dependent on the ability to raise non-dilutive capital, noted November 22, 2021.
$9.40
-0.45  -4.57%
19.6 million
$184.1 million
51.8 thousand
85.6 thousand
0.6
$1.38
$9.62
$9.85
11/26/2021
Tap to view 2 drugs
$4.84
-0.35  -6.74%
40.6 million
$196.5 million
63.1 thousand
301.4 thousand
0.21
$0.64
$5.07
$5.19
11/26/2021
Tap to view 2 drugs
$7.32
-0.16  -2.14%
9.5 million
$69.2 million
43.4 thousand
77.9 thousand
0.56
$2.00
$7.54
$7.48
11/26/2021
Tap to view 2 drugs
Drug Indication Stage News
Cytisine - (ORCA-2) Smoking cessation Phase 3 Phase 3 data due 1H 2022.
Cytisinicline (ORCA-V1) E-cigarette & vape cessation Phase 2 Phase 2 trial to be initiated 2Q 2022.
$5.17
-0.18  -3.36%
72.7 million
$375.6 million
275 thousand
563.3 thousand
0.49
$1.96
$5.31
$5.35
11/26/2021
Tap to view 9 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Semorinemab Alzheimer’s disease Phase 2 Phase 2 additional data presented at C-TAD conference November 10, 2021. Phase 2 top-line data did not meet endpoints - September 23, 2020.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1b Phase 1b data presented at AAIC July, 2021.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Semorinemab (LAURIET) Alzheimer’s disease Phase 2 Phase 2 top-line data met one of two co-primary endpoints August 31, 2021. Phase 2 top-line results reported a 42.2% reduction in the rate of cognitive decline with semorinemab compared to placebo, however the second co-primary endpoint and secondary endpoints not met, noted November 10, 2021.
ACI-3024 Alzheimer’s disease Phase 1 Phase 1 trial has completed.
ACI-35.030 Alzheimer’s Disease Phase 1/2 Phase 1b/2a further interim data showed that treatment led to strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments (ePHF), noted November 12, 2021.
ACI-24 Alzheimer’s disease (AD) Phase 2 Phase 2 interim analysis June 2, 2021, treatment well tolerated.
JACI-35.054 alternative anti-pTau vaccine Alzheimer’s disease Phase 1/2 Phase 1/2 trial ongoing.
$2.86
-0.23  -7.44%
11.2 million
$32 million
179.1 thousand
134.9 thousand
1.33
$0.20
$3.06
$3.09
11/26/2021
Tap to view 3 drugs
Drug Indication Stage News
Tozadenant Parkinson’s disease (PD) Phase 3 Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine Post stroke deficits Phase 3 Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301) OFF episodes of Parkinson’s disease (PD) Approved FDA Approval announced December 22, 2018.
$12.62
-0.78  -5.82%
61.2 million
$772.7 million
216.2 thousand
441.1 thousand
0.49
$3.56
$12.87
$13.40
11/26/2021
Tap to view 10 drugs
Drug Indication Stage News
ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Development to be discontinued - noted August 8, 2019.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 (THWART-1 and THWART-2) Common warts (verruca vulgaris) Phase 3 Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-450 Rheumatoid arthritis (RA) Phase 2b Phase 2b trial to be initiated 4Q 2021, noted November 2, 2021.
ATI-1777-AD-201 Atopic dermatitis Phase 2a Phase 2a data met primary endpoint, noted June 8, 2021. Phase 2b expected to initiate 1H 2022.
ATI-450 COVID-19 Phase 2a Phase 2a dosing commenced August 2020.
ATI-450 Hidradenitis suppurativa Phase 2 Phase 2 trial planned.
ATI-450 Psoriatic arthritis Phase 2 Phase 2 trial planned.
ATI-2138 Psoriasis Phase 1 IND submitted in October. Phase 1 trial to initiate before year end 2021.
$0.65
-0.02  -3.66%
119.3 million
$77.8 million
621.5 thousand
846.3 thousand
0.73
-$1.81
$0.68
$0.68
11/26/2021
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (Sufentanil) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. NDA resubmission planned.
$1.38
-0.05  -3.50%
26 million
$61.1 million
105.1 thousand
472.2 thousand
0.22
$0.57
$1.40
$1.43
11/26/2021
Tap to view 2 drugs
Drug Indication Stage News
CaPre (TRILOGY 1 and 2) Hypertriglyceridemia Phase 3 Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data August 31, 2020 also did not meet primary endpoint.
GTX-104 Subarachnoid hemorrhage (SAH) Phase 3 Phase 3 trial to be initiated in 2H 2022.
$8.69
-0.31  -3.44%
54.5 million
$473.4 million
7 thousand
17.1 thousand
0.41
$2.04
$9.00
$9.00
11/26/2021
Tap to view 6 drugs
Drug Indication Stage News
ADG106-P2001 Solid tumors Phase 2 Phase 2 results from combination trial 2022.
ADG116 Solid Tumors Phase 1 Phase 1 data of ADG-116 monotherapy (ADG116-1003) to be presented at ESMO-IO December 6, 2021. Phase 1 data of combination cohorts, ADG116 with toripalimab and ADG106 due 2022.
ADG126 Solid tumors Phase 1 Phase 1 data of ADG126 monotherapy (ADG126-1001) due 2H 2021. Phase 1 data of ADG126 (ADG126-1002) due 2022.
ADG116 combined with KEYTRUDA (pembrolizumab) - (ADG116-P001; KEYNOTE C97) Solid tumors Phase 1 Phase 1 trial to be initiated 2022.
ADG126 combined with KEYTRUDA (pembrolizumab) - (ADG126-P001; KEYNOTE-C98) Solid tumors Phase 1 Phase 1 trial to be initiated in 2022.
ADG106 combined w/ NIVOLUMAB Non-small cell lung cancer Phase 1/2 Phase 1b/2 trial initiated October 27, 2021.
$4.07
-0.21  -4.91%
156.2 million
$635.8 million
321.7 thousand
897 thousand
0.36
$2.64
$4.14
$4.28
11/26/2021
Tap to view 7 drugs
Drug Indication Stage News
Afami-cel (ADP-A2M4) - SPEARHEAD-1 Solid tumors Phase 1 Phase 1 preliminary data reported that all Cohort 1 patients had measurable persistence of transduced cells throughout the interventional phase of the trial with some maintaining high levels of persistence beyond 6 months post infusion. Median time to peak persistence was 1.1 weeks and median peak persistence was 218,827.9 copies/ug DNA, noted November 12, 2021.
AFP (ADP-A2AFP) Hepatocellular carcinoma Phase 1 Phase 1 data displayed one complete response and a disease control rate of 64% with stable disease for ≥16 weeks in two patients. Phase 1 top-line data has an acceptable safety profile. Dose escalation is complete September 5, 2021.
Afami-cel - (SPEARHEAD‑1) Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Phase 2 Phase 2 initial data at ASCO June 4-8, 2021. Abstract noted overall response rate was 39.3% (13/33), 41.4% (12/29) for synovial sarcoma; 25.0% (1/4) for MRCLS. Phase 2 trial expected to meet primary endpoint at final analyst later this year. Data reported an Independent Review overall response rate of 34% with 16 of 47 patients with partial responses (PR). The overall response rate was 36% in patients with synovial sarcoma, and 25% for patients with MRCLS, noted November 11, 2021. BLA filing due in 2022.
ADP-A2M4CD8 (SURPASS) Solid tumors Phase 1 Phase 1 data released September 16, 2021 - 4.5% of patients received CR, 31.8% received PR, 50% received SD, 13% received PD. Phase 2 trial, SURPASS-2, will start later 2021 for patients with esophageal and EGJ cancers.
ADP-A2M4CD8 (SURPASS-2) Esophageal and esophagogastric junction cancers Phase 2 Phase 2 trial initiated 3Q 2021, initial clinical data due 2022.
ADP-A2M4CD (SURPASS-3) Ovarian Cancer Phase 2 Phase 2 trial to be initiated in 2022.
Afami-cel (SPEARHEAD-2) Head & neck cancer Phase 2/3 Phase 2/3 initial clinical data due 2022.
$22.20
-0.44  -1.94%
78.3 million
$1.7 billion
35.5 thousand
168.2 thousand
0.21
$9.29
$22.64
$22.64
11/26/2021
Tap to view 9 drugs
Drug Indication Stage News
Camidanlumab tesirine Hodgkin lymphoma (HL) Phase 2 Phase 2 trial to complete 12-month follow up 1Q 2022 with preliminary results expected 1H 2022.
ZYNLONTA (Loncastuximab Tesirine) Diffuse Large B-Cell Lymphoma Approved FDA approval announced April 23, 2021.
Camidanlumab Tesirine and KEYTRUDA (pembrolizumab) Solid Tumors Phase 1b Phase 1b trial dose finding completed, noted November 2, 2021.
ZYNLONTA (Loncastuximab Tesirine-Ipyl) B-cell non-Hodgkin lymphoma Phase 2 Phase 2 data to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, December 11-14, 2021.
ZYNLONTA (loncastuximab tesirine) + IMBRUVICA (Ibrutinib) - (LOTIS-3) Diffuse Large B-Cell or Mantle Cell Lymphoma Phase 2 Phase 2 enrollment to continue 4Q 2021, interim data due at ASH December 11, 2021.
ZYNLONTA (Loncastuximab Tesirine) and RITUXAN (rituximab) - (LOTIS 5) Diffuse Large B-Cell Lymphoma Phase 3 Phase 3 safety lead-in to be completed 4Q 2021.
ADCT-601 Solid tumors Phase 1b Phase 1b trial to be initiated 1H 2022.
ADCT-901 Solid tumors Phase 1 Phase 1 first patients dosed, September 27, 2021.
ADCT-601 (mipasetamab uzoptirine) Solid tumors Phase 1b Phase 1b trial to be initiated 1H 2022.
$1.45
-0.05  -3.33%
195.8 million
$283.9 million
839.7 thousand
2.6 million
0.32
$2.79
$1.44
$1.50
11/26/2021
Tap to view 2 drugs
Drug Indication Stage News
ASCENIV (RI-002) Primary Immune Deficiency Diseases Approved FDA Approval announced April 1, 2019.
BIVIGAM Primary humoral immunodeficiency CRL FDA issued Complete Response Letter for PAS drug substance, but approved PAS for drug product.
$0.81
  +-0.55%
148.9 million
$121.2 million
2.5 million
7.2 million
0.34
$40.70
$0.81
$0.82
11/26/2021
Tap to view 6 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
ZIMHI (naloxone HCI Injection) Opioid overdose Approved Approved October 18, 2021.
APC-8000 (sublingual tadalafil) Erectile dysfunction NDA Filing Refusal to file letter received February 26, 2019.
Tempol COVID-19 Phase 2/3 Phase 2/3 trial initiated dosing September 2, 2021.
$8.22
  +0.00%
45.8 million
$376.4 million
0
1.5 million
0
-$17.49
$0.00
$8.22
11/26/2021
Tap to view 3 drugs
Drug Indication Stage News
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019. Findings were confirmed June 17, 2020.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
GOCOVRI (amantadine) Levodopa-Induced Dyskinesia + Parkinson's disease patients receiving levodopa and experiencing OFF episodes Approved FDA Approval announced August 24, 2017. Second approval to include treatment of OFF episodes in PD patients receiving levodopa announced February 1, 2021.
$28.12
-0.08  -0.28%
141.1 million
$4 billion
415.6 thousand
634.4 thousand
0.66
$6.09
$27.85
$28.20
11/26/2021
Drug Indication Stage News
$1.12
+0.04  +3.70%
26.9 million
$30.2 million
742.3 thousand
4.9 million
0.15
$2.33
$1.08
$1.08
11/26/2021
Tap to view 2 drugs
Drug Indication Stage News
ADi Psoriasis Phase 1/2 Phase 1/2 trial planned.
Avigan Reeqonus Qifenda (favipiravir) - PRESECO Covid-19 Phase 3 Phase 3 trial completed enrollment. Phase 3 top-line data reported that the trial did not meet its primary endpoint, noted November 12, 2021.
$0.38
-0.02  -4.23%
145.6 million
$56 million
1.7 million
5.2 million
0.32
$1.28
$0.38
$0.40
11/26/2021
Tap to view 4 drugs
Drug Indication Stage News
ADXS-PSA and KEYTRUDA (pembrolizumab) - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Phase 1 presentation at ASCO Genitourinary Cancers Symposium February 13, 2020 noted median overall survival (95% CI) of 33.7 months.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 trial closed - noted June 27, 2019.
ADXS-503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1 Part B data presented at ASCO June 4, 2021. Abstract noted Disease Control Rate (DCR) was 44% (4/9).
ADXS-504 Prostate Cancer Phase 1 Phase 1 trial initiation announced July 15, 2021 with initial data due 1H 2022.
  +0.00%
22 million
$
0
0
0
$0.00
$0.00
$0.00
11/11/2021
Tap to view 3 drugs
Drug Indication Stage News
ABP-450 (prabotulinumtoxinA) Migraine (prophylaxis) Phase 2 Phase 2 clinical study enrollment 1Q 2021. Phase 2 topline data expected 2H 2022.
ABP-450 (prabotulinumtoxinA) Cervical dystonia Phase 2 Phase 2 clinical study initiated 1Q 2021. Phase 2 topline data expected early 2022.
ABP-450 (prabotulinumtoxinA) Gastroparesis Phase 1 IND expected late 2021. Phase 2a clinical study to initiate 2022.
$9.80
-0.35  -3.45%
47.4 million
$464.1 million
462.7 thousand
925.1 thousand
0.5
-$6.36
$9.94
$10.15
11/26/2021
Tap to view 7 drugs
Drug Indication Stage News
ROCLATAN (netarsudil/latanoprost ophthalmic solution) Glaucoma Approved FDA Approval announced March 12, 2019.
RHOPRESSA (netarsudil ophthalmic solution)) Glaucoma Approved Approved December 18, 2017.
AR-13503 Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Phase 1 Phase 1 dose escalation safety evaluation due 1Q 2022.
AR-1105 (dexamethasone intravitreal implant) Macular edema due to RVO (retinal vein occlusion) Phase 2 Phase 2 top-line data July 27, 2020 noted treatment was well tolerated with no unexpected safety findings with sustained treatment effects. Phase 2 data displayed that the implant achieved targeted 6-month duration of efficacy, with improvements in BCVA and macular edema demonstrated for at least 6 months. Adverse events were consistent with other corticosteroid treatments, noted October 7, 2021.
ROCLATAN - (Mercury 3) Open Angle Glaucoma Phase 3 Phase 3 top-line data released September 24, 2020. Non-inferiority to Ganfort achieved.
AR-15512 (AVX-012) - COMET-1 Dry eye disease Phase 2b Phase 2b trial did not meet primary endpoints September 15, 2021. Meeting w/ FDA planned for 1Q 2022. Phase 3 trial planned.
AR-6121 ROCK Inhibitor Phase 1 IND filing expected 2H 2022.
$0.49
  +0.00%
121.4 million
$59.5 million
1.4 million
2.5 million
0.56
$0.99
$0.48
$0.49
11/26/2021
Tap to view 3 drugs
Drug Indication Stage News
MACRILEN (Macimorelin Acetate) Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
MACRILEN (Macimorelin Acetate) - DETECT(Study P02) Paediatric patients with suspected growth hormone deficiency (GHD) Phase 3 Phase 3 trial initiation announced May 13, 2021. Trial to be completed 3Q 2022.
$6.97
-0.1  -1.41%
119.8 million
$835 million
1.2 million
1.7 million
0.69
$5.53
$6.97
$7.07
11/26/2021
Tap to view 8 drugs
Drug Indication Stage News
AFM13 with KEYTRUDA (pembrolizumab) Hodgkin Lymphoma - Cancer Phase 1b Phase 1b data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%. Updated data to be presented at company-sponsored event in mid-December 2021.
AFM13 (REDIRECT) CD30-positive peripheral T cell lymphoma (PTCL) Phase 2 Phase 2 enrollment to be completed 1H 2022.
AFM24-101 EGFR-expressing solid tumors Phase 1/2 Phase 1/2a update on the dose escalation and initiation of the dose expansion cohorts due 2H 2021.
AFM13 + NK cells (AFM13-104) CD30-positive lymphomas Phase 1/2 Phase 1/2 interim data showed a 100% objective response rate with a 42% complete response rate in 12 patients. No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed, noted November 22, 2021. Updated results to be discussed on December 9, 2021.
AFM13 T-Cell, Cutaneous Lymphoma Phase 1/2 Phase 1/2 data presented at ASH 2020. Objective Response Rate (ORR) of 42%(6/14).
AFM24-102 and TECENTRIQ (atezolizumab) EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer Phase 1/2 Phase 1/2 trial planned for 4Q 2021.
AFM24-103/SNK-01 EGFR-expressing tumors, Non-small cell lung cancer, and Squamous cell carcinoma of the head and neck Phase 1/2 Phase 1/2 trial patient recruitment initiated November 8, 2021.
AFM28 Acute myeloid leukemia (AML) Phase 1 Phase 1 clinical trial to be initiated in 2H 2022.
$3.23
-0.11  -3.29%
256.8 million
$829.6 million
2.9 million
4.1 million
0.72
$20.19
$3.32
$3.34
11/26/2021
Tap to view 9 drugs
Drug Indication Stage News
Balstilimab (anti-PD-1) and Zalifrelimab - AGEN1884 (anti-CTLA-4) Cervical cancer Phase 2 Phase 2 data showed in 125 patients, the objective response rate (ORR) was 26%, with 9% of patients achieving a complete response (CR), and 17% of patients achieving a partial response (PR), noted September 17, 2021.
Zalifrelimab - AGEN1884 (anti-CTLA-4) Solid cancers Phase 1/2 Phase 3 expansion trial underway - noted August 6, 2020.
Balstilimab Cervical cancer BLA Filing BLA voluntarily withdrawn October 22, 2021.
AGEN1181 and balstilimab (anti-CTLA-4) Various cancers Phase 1 Phase 1 trial results presented showed 17 objective responses reported across nine cancers. Evidence of monotherapy activity, with OR=4. Objective responses noted in treatment refractory, poorly immunogenic tumors including microsatellite stable (MSS) colorectal cancer, ovarian cancer, MSS endometrial cancer, and melanoma; as well as responses in tumors not previously reported including pancreatic cancer, cervical cancer, visceral angiosarcoma, non-small cell lung cancer, and leiomyosarcoma. Phase 2/3 trials to be initiated in colorectal and gynecological cancer, noted November 12, 2021.
agenT-797 COVID-19 / Acute respiratory distress syndrome (ARDS) Phase 1/2 Phase 1 initial data released February 4, 2021. 3/4 patients were extubated and released after treatment. Phase 1/2 expansion trials underway.
MK-4830 Non-small cell lung cancer Phase 2 Phase 2 trial ongoing.
agenT-797 (iNKT) Multiple myeloma Phase 1 Phase 1 data showed no evidence of neurotoxicity or cytokine release syndrome. Early signals of tumor biomarker suppression and disease stabilization beyond 6 months, noted November 12, 2021.
AGEN2373 Solid tumors Phase 1 Phase 1 initial data presented at ASCO June 4, 2021. 5/22 patients showed stable disease.
AGEN1777 Solid tumors Phase 1 Phase 1 first patient dosed noted November 9, 2021.
$36.45
-0.8  -2.15%
54.3 million
$2 billion
373 thousand
417.7 thousand
0.89
$1.42
$36.93
$37.25
11/26/2021
Tap to view 14 drugs
Drug Indication Stage News
Mitapivat (ENERGIZE) Thalassemia Phase 3 Phase 3 trial to be initiated, noted November 3, 2021.
TIBSOVO (ivosidenib) IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
Mitapivat (AG-348) Pyruvate kinase deficiency PDUFA priority review PDUFA date under priority review February 17, 2022.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 enrolment to be completed 2021.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
TIBSOVO (ivosidenib) - (ClarIDHy) IDH1 mutant cholangiocarcinoma - cancer sNDA Filing sNDA filing announced March 1, 2021.
AG-270 Solid tumors Phase 1 Phase 1 enrolment has slowed due to COVID-19. A go/no-go decision is expected no later than 2022.
Vorasidenib (AG-881) Glioma Phase 3 Phase 3 enrolment has slowed as a result of COVID-19.
TIBSOVO (ivosidenib) Frontline AML with IDH1 mutation Approved FDA Approval announced May 2, 2019.
Vorasidenib (AG-881) IDHm low-grade glioma Phase 1 Phase 1 presentation at ASCO May 29, 2020. Median Progression-free Survival of 31.4 months.
Mitapivat (AG-348) - (ACTIVATE) Pyruvate Kinase Deficiency Phase 3 Phase 3 trial met primary endpoint - December 1, 2020. Data presented at EHA Virtual Congress, June 11, 2021. 40 percent (n=16) of patients randomized to mitapivat achieved a hemoglobin response, compared to 0 patients randomized to placebo (2-sided p<0.0001).
Mitapivat (AG-348) - RISE UP Sickle cell disease Phase 1 Phase 1 data to be presented at ASH December 11, 2021. Phase 2/3 trial to be initiated by end of 2021.
AG-946 Healthy volunteers Phase 1 Phase 1 data to be presented at ASH December 12, 2021.
Mitapivat (AG-348) - ESTIMATE open label Sickle Cell Disease Phase 2 Phase 2 open label poster to be presented at ASH December 12, 2021.
$6.45
-0.15  -2.27%
49.3 million
$318.1 million
84 thousand
139.1 thousand
0.6
$3.12
$6.58
$6.60
11/26/2021
Tap to view 2 drugs
Drug Indication Stage News
Pegzilarginase (AEB1102) - PEACE Arginase I deficiency Phase 3 Phase 3 data due December 2021.
AGLE-177 Homocystinuria Phase 1/2 Phase 1/2 initiation of dosing announced June 24, 2021.
$0.55
-0.05  -7.91%
121.4 million
$66.9 million
1.2 million
2.1 million
0.6
$6.12
$0.60
$0.60
11/26/2021
Tap to view 1 drug
Drug Indication Stage News
TWIRLA Contraceptive patch Approved FDA Approval announced February 14, 2020.
$1.44
+0.06  +4.35%
39.7 million
$57.2 million
315.2 thousand
351.8 thousand
0.9
$1.12
$1.44
$1.38
11/26/2021
Tap to view 12 drugs
Drug Indication Stage News
Ampligen CFS CRL CRL February 4, 2013.
Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 Phase 2 trial ongoing.
Ampligen, cisplatin and KEYTRUDA (pembrolizumab) Ovarian cancer Phase 2 Phase 2 trial is enrolling - noted August 2021.
Ampligen, Intron A Prostate Cancer Phase 2 Phase 2 trial has been initiated - noted August 2020.
Ampligen and interferon alpha-2b COVID-19 Phase 1/2 Phase 1/2a trial commencement of dosing announced November 25, 2020.
Ampligen human Rhinovirus hRV Phase 2a Phase 2a trial commenced.
Ampligen (intranasal) COVID-19 Phase 1 Phase 1 safety data results showed that no severe adverse events were reported and found the drug to be generally well tolerated, noted October 6, 2021. The biological samples are being analyzed for non-safety-related immunological activity with results expected 4Q 2021. Pre-IND for Phase 2 trial submitted September 28, 2021.
Ampligen (intravenous) COVID-19 Phase 2 Pre-IND for Phase 2 trial submitted September 28, 2021.
Ampligen (AMP-270) Pancreatic cancer Phase 2 IND approved for Phase 2 trial October 19, 2021.
Ampligen and pembrolizumab Metastatic triple-negative breast cancer Phase 1/2 Phase 1/2 trial ongoing, noted November 16, 2021.
Ampligen and celecoxib with or without Intron A Early-stage triple negative breast cancer Phase 1 IND authorized by FDA. Phase 1 enrollment ongoing, noted November 16, 2021.
Ampligen and celecoxib Refractory melanoma Phase 2 Phase 2 enrollment ongoing, noted November 16, 2021.
$2.67
-0.12  -4.30%
175 million
$467.1 million
2.4 million
2 million
1.21
$3.42
$2.75
$2.79
11/26/2021
Tap to view 4 drugs
Drug Indication Stage News
Auryxia Hyperphosphatemia Approved Approved Sept 5, 2014.
Vadadustat Anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis. PDUFA PDUFA date March 29, 2022.
Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients Approved sNDA FDA Approval announced November 7, 2017.
Vadadustat COVID-19 Phase 3 Phase 3 initiation announced July 14, 2020.